Fortitude Family Office, LLC Supernus Pharmaceuticals, Inc. Transaction History
Fortitude Family Office, LLC
- $372 Billion
- Q3 2025
A detailed history of Fortitude Family Office, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Fortitude Family Office, LLC holds 3 shares of SUPN stock, worth $135. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3
Previous 3
-0.0%
Holding current value
$135
Previous $95,000
50.53%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
330Shares Held
60.2MCall Options Held
234KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$468 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.04MShares$272 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$135 Million0.03% of portfolio
-
Armistice Capital, LLC New York, NY2.84MShares$128 Million2.08% of portfolio
-
Macquarie Group LTD Australia, C32.53MShares$114 Million0.14% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.41B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...